Learn more

SCLAVO SPA

Overview
  • Total Patents
    284
About

SCLAVO SPA has a total of 284 patent applications. Its first patent ever was published in 1973. It filed its patents most often in Italy, EPO (European Patent Office) and Japan. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are BEHRINGWERKE AG, KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION and LEE JONG Y.

Patent filings per year

Chart showing SCLAVO SPAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Rappuoli Rino 37
#2 Tarli Paolo 27
#3 Nencioni Luciano 22
#4 Lattanzi Filippo 19
#5 Vanni Riccardo 14
#6 Ratti Giulio 12
#7 Tabacco Alessandro 11
#8 Pizza Mariagrazia 11
#9 Tagliabue Aldo 10
#10 Parente Luca 10

Latest patents

Publication Filing date Title
EP0717049A1 Process for the extraction and purification of alfa1-antitrypsin (alfa1-pI) from cohn IV-1 fraction
EP0600480A2 Process for the extraction of factor VIII-von willebrand factor (FVIII:C-FVW) complex from total human plasma
EP0617049A1 Process for the isolation of highly purified factors IX, X and II from prothrombin complex or human plasma
EP0537456A1 Genetic vector for multiple stable integration of DNA sequences into the genome of the yeasts kluyveromyces lactis and saccharomyces cerevisiae and plasmids containing the same
US5206164A DNA encoding a synthetic peptide endowed with immunological activity and capable of inducing the production of antibodies with a high specificity towards alpha-fetoprotein
EP0551535A1 Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them
EP0496233A1 Pharmaceutical compositions for oral use containing low molecular weight heparin, their preparation and use
CA2057114A1 Synthetic oligonucleotides useful for the diagnosis of infections from different types of virus of the papilloma group and usage thereof
US5218089A Retro-inverso analogues of thymopentin and the method for their synthesis
EP0468393A1 Process for the extraction and purification of human recombinant gamma interferon
EP0462534A2 Acellular anti-pertussis vaccines
EP0468182A1 Pharmaceutical composition in powder form for nasal administration containing essentially calcitonin and a water-soluble excipient
CA2044191A1 Process for the purification of factor viii and factor viii obtained by said process
EP0468180A2 Buffer solutions containing collagenase, their preparation and use for diluting human sera
EP0457214A2 Method and reagent composition for the determination of alanine aminotransferase and HBsAg antigen in the same biological specimen
ITMI911068A1 Process for culturing mammal cells engineered through the use of microcarriers in which scale-up takes place using conventional culture media without the use of proteolytic enzymes
EP0499681A1 PCTD plasmid isolated from chlamydia trachomatis serotype D, its genes and proteins encoded by them; recombinant plasmids for the expression of said genes in heterologous systems as fused recombinant proteins, preparation of said recombinant proteins and their use in the formulation of vaccines and/or dianostics
EP0446850A2 Process for purifying recombinant human beta-interferon
CA2034618A1 Synthetic peptide derived from human lipocortin v and use thereof
US5229367A Antiinflammatory peptide derived from human lipocortin V